Who Paid My Doc
Rafael Mimbela
Neurodevelopmental Disabilities Donna, TX Medical Doctor
NPI 1730296047 CMS profile 1209836
702 E Expressway 83, Ste A3, Donna, TX 78537
General payments
$9,588
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Rafael Mimbela of Donna, TX is reported in the CMS Open Payments database as having received $9,588 across 628 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 88th percentile of Neurodevelopmental Disabilities profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,117 | 53 | |
| 2024 | General | $2,538 | 148 | |
| 2023 | General | $2,533 | 156 | |
| 2022 | General | $1,603 | 97 | |
| 2021 | General | $906 | 54 | |
| 2020 | General | $169 | 9 | |
| 2019 | General | $721 | 111 |
Beside peers
- Rafael Mimbela
- Neurodevelopmental Disabilities median
- Middle half of Neurodevelopmental Disabilities
- National median
In program year 2025, general payments to Rafael Mimbela were reported at $1,117. Among 64 Neurodevelopmental Disabilities profiles paid that year, the median was $136 and the middle half received between $67 and $819.
Show as a table
| Year | Rafael Mimbela | Neurodevelopmental Disabilities median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $721 | $138 | $34–$757 | $163 |
| 2020 | $169 | $63 | $23–$471 | $114 |
| 2021 | $906 | $158 | $43–$1,017 | $132 |
| 2022 | $1,603 | $225 | $76–$1,106 | $149 |
| 2023 | $2,533 | $228 | $73–$994 | $160 |
| 2024 | $2,538 | $167 | $57–$1,310 | $164 |
| 2025 | $1,117 | $136 | $67–$819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
119
Drug cost
$5,925
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Oxcarbazepine | Generic | 37 | $4,467 | |
| Carbamazepine | Generic | 13 | $767 | |
| Levetiracetam | Generic | 32 | $584 | |
| Topiramate | Generic | 37 | $107 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 13 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| Briviact |
|
$522 | — | — |
| JORNAY PM |
|
$457 | — | — |
| Qelbree |
|
$427 | — | — |
| VALTOCO |
|
$356 | — | — |
| Epidiolex |
|
$188 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 13 in the dashboard with a free accountRecords
628 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurodevelopmental Disabilities in Texas
Satish Agadi
Neurodevelopmental Disabilities · Galveston, TX
Rafael Villalobos-Nieto
Neurodevelopmental Disabilities · Harlingen, TX
Saeed Kahkeshani
Neurodevelopmental Disabilities · Baytown, TX
Uloma Labrie
Neurodevelopmental Disabilities · Dallas, TX
Pamela Lupo
Neurodevelopmental Disabilities · Webster, TX
Linda Nguyen
Neurodevelopmental Disabilities · Dallas, TX
Related records
Neurodevelopmental Disabilities in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Neurodevelopmental Disabilities
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.